Archivi categoria: EGFR

B9991027

A PHASE 2, OPEN LABEL STUDY TO EVALUATE SAFETY AND CLINICAL ACTIVITY OF AVELUMAB (BAVENCIO (REGISTERED)) IN COMBINATION WITH AXITINIB ((INLYTA (REGISTERED)) IN PATIENTS WITH ADVANCED OR METASTATIC PREVIOUSLY TREATED NON-SMALL CELL LUNG CANCER OR TREATMENT NAÏVE CISPLATIN-INELIGIBLE UROTHELIAL CANCER (JAVELIN MEDLEY VEGF)

STADIO
IIIB-IV

Il protocollo è attivo nei seguenti centri

Scopri


KEYNOTE-789

STUDY OF PEMETREXED + PLATINUM CHEMOTHERAPY WITH OR WITHOUT PEMBROLIZUMAB (MK-3475) IN ADULTS WITH TYROSINE KINASE INHIBITOR- (TKI)-RESISTANT EPIDERMAL GROWTH FACTOR RECEPTOR- (EGFR)-MUTATED METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)

STADIO
IV

Il protocollo è attivo nei seguenti centri

Scopri





CEGF816X2201C

A PHASE II, MULTICENTER, OPEN-LABEL STUDY OF EGF816 IN COMBINATION WITH NIVOLUMAB IN ADULT PATIENTS WITH EGFR MUTATED NON-SMALL CELL LUNG CANCER AND OF INC280 IN COMBINATION WITH NIVOLUMAB IN ADULT PATIENTS WITH CMET POSITIVE NON-SMALL CELL LUNG CANCER

STADIO
IV

Il protocollo è attivo nei seguenti centri

Scopri


OSIRIS

(OSIMERTINIB RECHALLENGE TKI IN SUBSEQUENT LINE OF THERAPY) A PHASE II, NONCOMPARATIVE, OPEN LABEL, MULTICENTRE, STUDY OF AZD9291 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC EGFR MUTATED “T790M UNDETECTABLE OR UNKNOWN” NON-SMALL CELL LUNG CANCER (STAGE IIIB-IV) AFTER NO IMMEDIATE PRIOR EGFR TKI

STADIO
IIIB/IV

Il protocollo è attivo nei seguenti centri

Scopri





BEVERLY

STUDY COMPARING BEVACIZUMAB + ERLOTINIB VS ERLOTINIB ALONE AS FIRST LINE TREATMENT OF PATIENTS WITH EGFR MUTATED ADVANCED NON SQUAMOUS NON SMALL CELL LUNG CANCER

Il protocollo è attivo nei seguenti centri

Scopri



















ADAURA

A PHASE III, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED MULTI-CENTRE, STUDY TO ASSESS THE EFFICACY AND SAFETY OF AZD9291 VERSUS PLACEBO, IN PATIENTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION POSITIVE STAGE IB-IIIA NON-SMALL CELL LUNG CARCINOMA, FOLLOWING COMPLETE TUMOUR RESECTION WITH OR WITHOUT ADJUVANT CHEMOTHERAPY 

STADIO
IB-IIIA

Il protocollo è attivo nei seguenti centri

Scopri